Postdoctoral Research Fellow in Kidney Cancer at City of Hope, Los Angeles
Joined July 2019
- Tweets77
- Following79
- Followers99
- Likes182
Novel targets in mRCC remain a critical unmet need, especially in the IO-resistance setting.
🎬Watch here as I explain MOAs of the most promising novel targets in early phase testing.
#ESMO26
At #ESMO26, Rahul Winayak, MD (@cityofhope) explains new metastatic #RCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome #immunotherapy resistance.
🎥 WATCH: targetedonc.com/view/rahul-w…
#KidneyCancer #Oncology | @RWinayak @CityofHope_GU
Rahul Winayak retweeted
CD70. ENPP3. HPK1. GPR65. All promising targets in #kidneycancer, but what is know about their prognostic/predictive value? Are they enriched in pts with angiogenic or immunogenic profiles? My brilliant @cityofhope postdoctoral fellow @RWinayak takes aim at these questions in his #ESMO26 poster. Do stop by!
@AndreaNecchi @tompowles1 @brian_rini @DrChoueiri @shilpaonc @apolo_andrea @TDorffOnc @neerajaiims @PGrivasMDPhD @g_procopio_ @gbanna74 @ravikanesvaran @OncoAlert
Excited to share our #ESMO26 abstract on emerging targets in mRCC. Analysis of 2,134 RCC transcriptomes identified immunogenic (GPR65/HPK1) and angiogenic (ENPP3/CD70) programs linked to improved outcomes with IO vs non-IO therapy, informing future combination strategies.
Thanks @OncLive for a great interview on my #ESMO26 abstract highlighting novel targets in mRCC. Excited to share the latest developments during Sunday's X takeover, including @montypal's presentation of initial Ph1 Xmab819 (ENPP3xCD3) data. 🚀
Thank you to @RWinayak of @cityofhope for sharing insights from research on novel target expressions in renal cell carcinoma, being presented at @myESMO #ESMO26
Excited to share our #ESMO26 abstract on emerging targets in mRCC. Analysis of 2,134 RCC transcriptomes identified immunogenic (GPR65/HPK1) and angiogenic (ENPP3/CD70) programs linked to improved outcomes with IO vs non-IO therapy, informing future combination strategies.
Rahul Winayak retweeted
We're being taken over! During #ESMO26, follow along as #oncology experts take over OncLive's social accounts and share exclusive insights from @myESMO in Madrid.
Stay tuned all meeting for updates from @GhosnMd, @RWinayak, @benweinbergmd, and @maryam_lustberg
Impressed by the innovative work of NCI CP-CTNet at #SWOGFall2026. From Lynch syndrome vaccine trials to AR blockade strategies in NMIBC, these Phase I/II studies are generating critical signals for cancer prevention.
🌟Need to translate these promising findings into Ph3 trials – at Chicago, IL
Wonderful talk by @VanitaNoronha at #IUCS26 on the importance of geriatric assessment in the treatment of elderly patients with cancer.
Intriguing to see the range of ongoing pragmatic trials at @TataMemorial
to optimise and de-escalate treatment for elderly patients with cancer
Fascinating talk by the great @NickSalgia at #IUCS26 on applying the @meeturoIT scoring system to real-world data:
🔬 Group 1 pts show angiogenic TME; higher groups display more immunogenic TME
➡️ MEET-URO 33 is prospectively investigating predictive ability of Meet-URO
@montypal
Rahul Winayak retweeted
Many thanks to @Hoomandjaladat for the invitation to give @USC_Urology Grand Rounds a moment ago. My main message: If we want to get trials done in non-clear cell #kidneycancer, we need to collaborate. Proud to have established (w @siadaneshmand, @TDorffOnc, @AdityaBagrodia, @DrRanaMcKay, @KidneyCancerDoc & others) a network with @uscnorris, @UclaUrology, @UCIrvineHealth, @KPSCalResearch, @hoaghealth, @UCSD, @CedarsSinai & other terrific #SoCal institutions to get GU research done! My closing slide:
RCC variant histologies represent a remarkably diverse group of diseases. An outstanding overview of landmark and ongoing trials in the field by @montypal. Particularly exciting is STELLAR-304, evaluating zanzalitinib plus nivolumab in the frontline nccRCC setting. @_MDEducation – at Winthrop, MA
Rahul Winayak retweeted
You are too kind @JCohenMD! It was former @ASCO President @RobinZo41054013 that inspired me to get involved in our state society. It's been an honor to lead @MOASC_Office & it's served as a wonderful vehicle for my youngest mentees!
Dr. Sumanta Paul @montypal continues to have a profound impact on mentoring the next generation of cancer researchers and medical providers. As president of @MOASC_Office his trainees in the photo below are bringing meaningful research to the #SpotlightonOncology2026 with MOASC. Dr. Pal's efforts to train our future cancer doctors will benefit an immeasurable number of patients. @cityofhopeoc @COHMedOnc @cityofhope @ClaytonLauMD
Rahul Winayak retweeted
Congratulations to the recipients of the 2026 KCRS Merit Awards for Clinical Research!
This year's honorees are:
• Karie Runcie, Columbia University
• Rahul Winayak, City of Hope Comprehensive Cancer Center
• Hedyeh Ebrahimi, City of Hope Comprehensive Cancer Center
Their research represents excellence in clinical investigation and reflects KCRS's commitment to improving outcomes for people living with kidney cancer.
Congratulations to all of this year's recipients!
#KCRS26 #AcceleratingCures
Rahul Winayak retweeted
Could not be prouder of @ActuallyGZhang who graduated from @pomonacollege & joined us at @cityofhope as a research associate. Alongside @jadonfann & @DVCastro_, he has worked nonstop to lead a team of undergraduates (with substantial guidance from @ReginaBarCar @charlesbnguyen @NazliDizman et al) to put together this extensive work, characterizing the patterns of #kidneycancer trials in the US. The link between social vulnerability indices & trial availability is a novel one - we need to remedy this somehow.
‼️Our study assessing the availability of 289 #RenalCellCarcinoma clinical trials in the US is out now in @JCOOP_ASCO: ascopubs.org/doi/10.1200/OP-… 🎉
Our analysis asked 2️⃣ questions:
•Where are RCC trials in the US?
•Are trials disproportionately absent from certain regions?
🧵⬇️
Rahul Winayak retweeted
We were honored to have @VirajMaster deliver the keynote of our @CityofHope Annual GU Research Symposium to help shape our upcoming clinical trial and correlative biomarker designs.
What better way to thank him than with a Peking duck? 🦆
Early onset RCC exhibits distinct biology, highlighting the need for further research to optimise treatment for this patient population as eloquently shown by @EbrahimiHedyeh at #KCRS26 – at Winthrop, MA
Rahul Winayak retweeted
I always enjoy talks from @MikeSerzanMD @DanaFarber who offers an excellent overview of #ASCO26 abstracts at #KCRS26. Excellent overview of radio pharmaceuticals for #kidneycancer incl data from RADICALS (@DrRanaMcKay @UCSDCancer); appreciate the shoutout for LUTEON. Great discussion as well of selection criteria for adjuvant therapy.
Wonderful overview of the role of radiosurgery for brain metastases by @Raj_Singh_MD at #KCRS26. Highly stimulating discussion on the need for personalised therapy to balance upfront systemic therapy with radiosurgery for brain metastases
Rahul Winayak retweeted
Incredibly proud of this terrific bunch! I miss @NickSalgia (now at @RoswellPark) & @EbrahimiHedyeh (now at @BIDMC_Medicine) dearly, but proud that they continue to make such waves in the world of #kidneycancer! Join us at #KCRS26 this afternoon to hear @RWinayak's talk, one of my exceptional new fellows who has developed some novel clinical biomarkers of IO benefit. @DrChoueiri @HHammersMD @DrRanaMcKay @DrRaviSalgia @neerajaiims @katy_beckermann @VivekSubbiah @PGrivasMDPhD @OncoAlert
It’s becoming a recurring theme for @CityofHope fellows (and alumni) of the @MontyPal team to need extra luggage to bring home all the awards from #KCRS26. Congrats @RWinayak @NickSalgia and @EbrahimiHedyeh!!
Rahul Winayak retweeted
Mind blowing 🤯 talk from #DrBertrandRouty @UMontreal on the #microbiome in #kidneycancer & beyond. Beautiful data in @Nature & @NatureMedicine very recently showing (convincingly) the impact of diet on therapeutic outcomes! Could Lactobacillus johnsonii be a key mediator? An obesogenic diet? Need more studies!
